Fenfluramine · Fintepla

Small molecule

Also known as ZX008

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy (label: seizures of Dravet syndrome and Lennox-Gastaut syndrome, age 2 and older), Dravet Syndrome, Lennox-Gastaut Syndrome, Developmental and Epileptic Encephalopathies

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Rett Syndrome · Phase 3 · investigational in the US

Also approved (2)
JP
  • Use as an adjunctive therapy with other antiepileptic drugs to treat epileptic seizures in patients with Dravet syndrome who have not responded sufficiently to other antiepileptic drugs
Product first approved 2022PMDA
EU
  • Treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
Product first approved 2020EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (11)
Developmental and Epileptic Encephalopathies
NCT06118255 · UCB BIOSCIENCES, Inc.
2024-05-21 – 2026-09-01 · Dravet Syndrome
What this study did
NCT05560282 · University Health Network, Toronto
2023-01-11 – 2025-05-13 · Dravet Syndrome, Dravet Syndrome, Intractable
What this study did
NCT03936777 · Zogenix, Inc.
2019-04-22 – 2025-05-08 · Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy
What this study did
NCT02823145 · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
2016-06-08 – 2023-01-27 · Dravet Syndrome
What this study did
NCT03299842 · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
2017-07-12 – 2018-07-05 · Dravet Syndrome
What this study did
Epilepsy
NCT05064878 · Zogenix, Inc.
2022-03-08 – 2027-11-08 · CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
What this study did
NCT03790137 · Elizabeth Anne Thiele
2019-05-31 – 2024-07-19 · Photosensitive Epilepsy
What this study did
Rett Syndrome
Phase 2 (5)
Developmental and Epileptic Encephalopathies
NCT02655198 · KU Leuven
2016-01 – 2024-12 · Epilepsy, Lennox Gastaut Syndrome
What this study did
Epilepsy
NCT04289467 · Children's Hospital of Orange County
2023-06-16 – 2026-12-31 · Infantile Spasm
What this study did
Other / comorbidity
NCT03861871 · NYU Langone Health
2019-10-29 – 2022-10-24 · CDD
What this study did
NCT00000314 · National Institute on Drug Abuse (NIDA)
1994-09 – 1999-08 · Cocaine-Related Disorders
What this study did
NCT00000506 · National Heart, Lung, and Blood Institute (NHLBI)
1983-05 – 1988-04 · Heart Diseases, Obesity, Vascular Diseases
What this study did
Phase 1 (3)
Developmental and Epileptic Encephalopathies
NCT03467113 · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
2018-01-19 – 2020-06-24 · Dravet Syndrome, Lennox Gastaut Syndrome
What this study did
Other / comorbidity
NCT06679413 · UCB BIOSCIENCES, Inc.
2024-12-04 – 2025-06-12 · Healthy Study Participants
What this study did
NCT00000313 · National Institute on Drug Abuse (NIDA)
— · Cocaine-Related Disorders
What this study did
Phase 4 (4)
Developmental and Epileptic Encephalopathies
NCT07112365 · The University of Texas Health Science Center, Houston
2026-04-27 – 2028-03-31 · Dravet Syndrome
What this study did
NCT06598449 · University of Colorado, Denver
2024-10-22 – 2027-07 · Dravet Syndrome (DS), Children Under 2 Years
What this study did
NCT05232630 · Hospital Ruber Internacional
2022-10-20 – 2024-12-31 · Refractory Epilepsy, SYNGAP1 Encephalopathy, STXBP1 Encephalopathy With Epilepsy, Inv Dup(15) Encephalopathy, Multifocal or Bilateral Malformations of Cortical Development, Continuous Spike and Waves During Slow Sleep
What this study did
Other / comorbidity
NCT05026398 · University of Oxford
2021-04-12 – 2022-06-22 · Cognitive Function
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07651293 · Imperial College Healthcare NHS Trust
2026-07-01 – 2028-12 · Depression - Major Depressive Disorder
What this study did

Competitive landscape

This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fenfluramine (Fintepla): this drugApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001).
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022).
RufinamideApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Fintepla (Fenfluramine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 4EpilepsyRecruiting
Est. primary completion 2026-12 · NCT06598449 · CT.gov ↗
What to watch
Phase 2EpilepsyRecruiting
Est. primary completion 2026-12-31 · NCT04289467 · CT.gov ↗
What to watch
2027 (2)
September 2027 (1)
Phase 4EpilepsyRecruiting
Est. primary completion 2027-09-30 · NCT07112365 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3EpilepsyActive not recruiting
Est. primary completion 2027-11-08 · NCT05064878 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
Early phase / not applicableDepression - Major Depressive DisorderNot yet recruiting
Est. primary completion 2028-07 · NCT07651293 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 3Rett SyndromeRecruiting
Est. primary completion 2029-02-06 · NCT07503444 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 December 2025Topline resultGEMZ phase 3 study in CDKL5 deficiency disorder meets primary endpoint
27 June 2025Topline resultGEMZ Phase 3 (NCT05064878) in CDKL5 deficiency disorder met its primary and key secondary endpoints
UCB · Source ↗